Key Takeaways
- Volume-led 30% revenue growth, margin surge: FY23 revenue grew 29.71% YoY on higher volumes and better realizations, while Q4 EBITDA margin jumped 751 bps YoY aided by a one-off R&D expense drop.
- Tender delays choked offtake, inventory built in response: Slowness in global TB tenders persisted through Q4, suppressing Rifa-S dispatches. Management ran the plant at full capacity without a shutdown, building inventory to meet anticipated demand when tenders open.
- Capex cycle nears first milestone, API block delayed by a quarter: The new warehouse, R&D center, and API block are now expected by September 2023, a one-quarter slip as management chose to add a pilot facility. The fermentation block remains on track for end of CY2024.
- Rifapentine adoption is a structural demand tailwind: The WHO’s shift to 3HP therapy means more Rifa-S is needed per patient, a dynamic management called “very, very positive” for the intermediate business.
- What to watch next quarter: Whether the delayed tenders actually convert inventory into revenue, the September commissioning of the API block, and any update on the six-product R&D pipeline as the pilot facility comes online.
Demand & Volume Dynamics
- Tender logjam defined the quarter: Global TB tenders, including the Global Fund, were delayed by one to two quarters, keeping Rifa-S offtake low. Tenders began opening gradually, explaining the slight sequential growth.
- Rifamycin-O steady, Rifa-S stuck: Rifa-O saw decent demand and sufficient dispatches. Rifa-S, being largely tender-driven, remained on the lower side.
- Full-tilt production, no shutdown: Unlike the prior two years, the company skipped its traditional two-month plant shutdown, running at 100% capacity to build inventory. Surplus production is held in the warehouse, ready for dispatch once tenders open fully.
- Input costs managed, China not a threat: Input prices fluctuate seasonally but not materially. All inputs are domestically sourced. Prices from China for competing products have only moved upwards.
Rajneesh Anand: "The plant is in very good health and the shutdown, which we took last two years, we had taken practically after seven years... So in my view, we will continue to produce through the next year."
Capex Program & Timeline
- Three-part build underway: The capex program comprises a new GMP warehouse, an R&D center, and an API block (Phase 1), followed by a new fermentation facility (Phase 2). Total capitalized so far: ~₹16 Cr, with ₹20 Cr in CWIP and ~₹10 Cr in capital advances for equipment.
- API block delayed by design: The API block, originally on track, was delayed by roughly one quarter because management decided to add a pilot facility on one floor, a modification deemed important for long-term capabilities.
- September 2023 milestone: The GMP warehouse is already complete. The R&D center and API block are expected to be operational by September 2023. The fermentation block, the last leg, is expected by end of calendar year 2024.
- Commercialization lag built in: After the API block is ready in September, expect 1–2 months for validation/exhibit batches, then 6 months of stability studies, then regulatory approval. Realistically, the API block starts contributing to revenue in FY25, or perhaps late FY24.
Sachin Patel: "Our project was going on reasonably well... but within the project we decided to make some modifications because we felt that they would be important for the long-term future of our business. And those modifications essentially led to the delay of a quarter or so, which in a way we expected when we decided this particular call, but we still felt it would be worthwhile the delay considering the capabilities that now we would have in this particular block."
Product & Pipeline Strategy
- Fermentation-only focus: The company plans to work only on products where intermediates are fermentation-based, believing that is where it can add maximum value. It has no intention of entering job-work arrangements.
- Rifapentine: a structural demand boost: The WHO’s adoption of 3HP (rifapentine-based) therapy over rifampicin-based treatment is positive for Rifa-S demand. Rifapentine requires a higher dose per patient, and the conversion ratio of Rifa-S to Rifapentine is lower than to Rifampicin, meaning more Rifa-S is consumed per unit of finished drug.
- Rifaximin patent openings in stages: Certain European markets are expected to open over the next year. The US patent opens in 2028–29, possibly earlier depending on formulator actions. Currently, all Rifa-O supply serves ROW markets, not the innovator.
- New API is B2B, not tender-based: Unlike the TB business, the new high-value API under development will be a commercial B2B product, not a B2G tender-driven product.
- Six-product R&D pipeline, no guarantees: Lab work is ongoing on six products. Scale-up to pilot and then commercial batches is the next step, dependent on the CGMP pilot facility being ready in September. Management cautioned that fermentation scale-up is inherently risky and declined to guarantee all products will commercialize.
Sachin Patel: "Fermentation is a tough cookie. We need to move to the next stage which we will be able to only after September once our pilot facilities are ready... I don't think in science I would give a guarantee stamp that everything will work out the way we want to."
Margins & Cost Structure
- Q4 margin spike aided by R&D timing: Q4 FY23 EBITDA margin improved 751 bps YoY. Other expenses halved QoQ because the prior quarter included ~₹3 Cr in R&D expenses that did not recur in Q4. Better realizations also helped offset higher utility costs.
- Employee cost leverage from no-shutdown decision: Employee cost remained largely flat while revenue grew ~30% YoY. Management attributed this to running the plant continuously rather than automation, as the fermentation plant operates around the clock.
- No shutdown benefit is structural for now: The decision not to shut down avoided the fixed-cost absorption drag of idle months. Management expects to continue producing through the next year without a shutdown, given the plant’s good health.
Balance Sheet & Cash Position
- Deposits shifted to non-current: Bank deposits previously maturing within 12 months (~₹10 Cr) were renewed for tenures exceeding 12 months, moving them from current assets to non-current assets. For FY24, long-term deposits are likely to remain larger than short-term deposits.
- Capital advances drive non-current asset rise: Other non-current assets rose to ₹10 Cr, driven primarily by ₹8.835 Cr in capital advances for equipment under the capex program.
- Inter-corporate deposits stable: Loans under current assets (~₹17 Cr) are expected to remain in a similar range next year.
- Deposit utilization tied to capex: Deposits will be drawn down for the expansion plan, so the mix of short-term vs. long-term depends on quarterly and monthly cash needs.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| API block, R&D center, GMP warehouse operational | Capex completed, validation batches begin | September 2023 |
| API block revenue contribution | First commercialization after exhibit batches, stability, and regulatory approval | FY25, or possibly late FY24 |
| Fermentation block operational | Last leg of current capex cycle | End of calendar year 2024 |
| Production continuity | No plant shutdown planned, continue at full capacity | Through next year (FY24) |
| Product strategy | Only fermentation-based intermediates, own manufacturing and sales, no job work | Foreseeable future |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹28.17 cr, vs ₹28.76 cr in Q4 FY22 |
| EBITDA | ₹14.93 cr, up 14.12% YoY |
| EBITDA margin | 52.98%, up 751 bps YoY; better realizations and lower R&D investment of about ₹3 cr helped margins |
| PAT | ₹11.69 cr, vs ₹9.79 cr in Q4 FY22 |
| PAT margin | 41.50% |
| EPS | ₹8.05 |
| FY23 revenue | ₹148.97 cr, up 29.71% YoY; growth driven by rise in volumes and better realizations |
| FY23 EBITDA | ₹74.22 cr, up 27.86% YoY |
| FY23 EBITDA margin | 49.82% |
| FY23 PAT | ₹57.97 cr, up 32.88% YoY |
| FY23 PAT margin | 38.91% |
| FY23 EPS | ₹39.90 |
| Total capex plan | ₹200 cr, spanning over two-plus years |
| Capex capitalized so far | ₹16 cr |
| CWIP | ₹20 cr |
| Capital advances for equipment | ₹10 cr |
| Fermentation block phase one investment | ₹80 cr out of ₹200 cr |
| R&D block cost | ₹42 cr total: one pilot suite ₹25 cr, two others ₹8 cr, lab ₹9 cr |
| Additional capex beyond ₹200 cr | ₹160 cr for two more phases, not yet planned |
| Production capacity utilization | 100%, vs 70–75% in the previous year; no plant shutdown taken this year |
| Q4 other expenses | ₹1.86 cr, vs ₹4.15 cr QoQ; prior quarter included one-off R&D expenses |
| Peak quarterly revenue | ~₹48 cr in Q2 FY23 |
| FY24 revenue growth expectation | 25% to 30% YoY, implying top line of around ₹190–200 cr (per an analyst's math) |
| API block expected completion | September 2023; commercial sales expected Q1 FY25 after validation and stability |
| Fermentation block expected completion | End of calendar year 2024 |